Want to see BHST full AI Analyst Report?
Top Page
BioHarvest Sciences
(NASDAQ:BHST)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▲(0.00% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial quality (ongoing losses and persistent cash burn) and a bearish technical setup (price below key moving averages and negative MACD). Offsetting factors include strong gross margins and revenue progress, plus earnings-call positives around improved cash and longer-term CDMO opportunity—though these are tempered by lowered 2026 guidance and continued EBITDA losses.
Positive Factors
Revenue Growth and Gross Margin
Strong multi-year revenue expansion and gross margins near 59% indicate meaningful product demand and attractive unit economics. If sustained, this combination can provide operating leverage as BioHarvest scales production and commercial partnerships.
Negative Factors
Persistent Losses and Cash Burn
BioHarvest has not yet converted strong gross margins into operating profitability or positive cash generation. Continued losses and cash burn could require financing or constrain investment, leaving execution dependent on achieving scale and disciplined expense control.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
Strong multi-year revenue expansion and gross margins near 59% indicate meaningful product demand and attractive unit economics. If sustained, this combination can provide operating leverage as BioHarvest scales production and commercial partnerships.
Read all positive factors
BioHarvest Sciences (BHST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.34M
Dividend YieldN/A
Average Volume (3M)78.84K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth17.50%
EPS Growth24.63%
CountryUS
Employees89
SectorConsumer Defensive
Sector Strength42
IndustryAgricultural - Commodities/Milling
Share Statistics
EPS (TTM)-0.54
Shares Outstanding22,667,843
10 Day Avg. Volume86,360
30 Day Avg. Volume78,844
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside350.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$42.89M
BioHarvest Sciences Business Overview & Revenue Model
Company Description
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingred...
How the Company Makes Money
BioHarvest Sciences primarily makes money by selling products derived from its proprietary plant-cell cultivation (“botanical synthesis”) technology. Its revenue model is based on (1) direct sales of finished nutraceutical/health-and-wellness prod...
BioHarvest Sciences Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 30, 2026
Earnings Call Sentiment Neutral
The call balanced significant strategic progress and validation—most notably the major fragrance CDMO contract, stronger cash position, and government-backed technology grants—against near-term revenue guidance cuts, higher operating expenses, and continued adjusted EBITDA losses. Management is pivoting resources toward higher-margin CDMO opportunities and capacity build-out, accepting lower near-term product revenue (VINIA) in order to pursue longer-term profitability and scale. Key positives are the sizeable contract pipeline and material cash increase; key negatives are reduced 2026 top-line guidance and short-term profitability pressures stemming from reallocated marketing and development spend.Positive Updates
First Major CDMO Manufacturing & Supply Agreement
Signed first-ever CDMO manufacturing and supply agreement for a UAE-based customer for a rare luxury fragrance with a 20-ton commitment. Company states potential to translate to $20 million to $30 million in revenue across 2027–2028 and signaled an expectation of ~$180 million for the first five years of manufacturing for this fragrance category.
Negative Updates
Total Revenue Guidance Reduced
Full-year consolidated revenue guidance lowered to $37 million–$40 million from prior range of $42 million–$48 million, reflecting reallocation of spend toward CDMO capacity build-out and conservative go-to-market investments.
Read all updates
Q2-2026 Updates
Positive
Negative
First Major CDMO Manufacturing & Supply Agreement
Signed first-ever CDMO manufacturing and supply agreement for a UAE-based customer for a rare luxury fragrance with a 20-ton commitment. Company states potential to translate to $20 million to $30 million in revenue across 2027–2028 and signaled an expectation of ~$180 million for the first five years of manufacturing for this fragrance category.
Read all positive updates
Company Guidance
Management tightened 2026 guidance, lowering consolidated revenue to $37–$40M (from $42–$48M) while still targeting consolidated EBITDA breakeven in 2027 and forecasting a consolidated EBITDA loss of $3–$5M (was $3–$4M); CDMO revenue was tightened to $4–$5M (from $4–$6M) with CDMO full‑year EBITDA loss cut to $1.5–$2.5M (from $4–$5M). The VINIA D2C business was revised to $33–$35M in revenue (from $38–$42M) with an expected EBITDA loss of $1.5–$2.5M (priorly a $0.5–$2M gain); VINIA has ~95,000 active customers (up ~2% YoY and vs Q1), implemented up to 20% pricing increases for certain new subscribers in June, and will launch single‑dose Daily Chews in September. Management expects limited production and revenue recognition for the new 20‑ton fragrance CDMO supply agreement to begin in H1 2027 and says the deal could translate to $20–$30M of revenue in 2027–2028 (and previously projected ~$180M over the first five years), while cash and deposits stood at $16.2M at June 30, 2026 (vs $3.7M a year earlier); Q2 results included revenue of $8.8M (+3.8% YoY), gross profit $5.1M (58% margin), net loss $3.7M ($0.17/sh), and adjusted EBITDA loss $1.6M.BioHarvest Sciences Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
41
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.48M | 34.51M | 25.19M | 12.67M | 5.50M | 2.10M |
| Gross Profit | 20.91M | 20.48M | 13.94M | 5.63M | 1.22M | 670.00K |
| EBITDA | -7.29M | -6.71M | -9.72M | -9.76M | -9.13M | -8.64M |
| Net Income | -11.07M | -11.13M | -12.91M | -12.56M | -11.24M | -9.83M |
Balance Sheet | ||||||
| Total Assets | 44.57M | 47.66M | 25.00M | 15.00M | 9.39M | 10.21M |
| Cash, Cash Equivalents and Short-Term Investments | 16.22M | 23.02M | 2.39M | 5.36M | 1.74M | 4.12M |
| Total Debt | 17.55M | 14.10M | 13.82M | 22.34M | 10.56M | 2.66M |
| Total Liabilities | 24.80M | 22.22M | 23.67M | 29.86M | 15.32M | 7.35M |
| Stockholders Equity | 19.76M | 25.45M | 1.33M | -14.85M | -5.93M | 2.85M |
Cash Flow | ||||||
| Free Cash Flow | -10.95M | -9.58M | -9.52M | -10.00M | -10.50M | -8.43M |
| Operating Cash Flow | -8.71M | -7.23M | -6.68M | -8.52M | -9.24M | -6.79M |
| Investing Cash Flow | -3.25M | -2.37M | -3.03M | -1.47M | -1.26M | -1.64M |
| Financing Cash Flow | 23.50M | 30.19M | 6.78M | 13.56M | 8.14M | 10.77M |
BioHarvest Sciences Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $55.30B | 54.55 | 4.08% | 0.81% | 3.70% | -26.39% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
51 Neutral | $1.39B | -0.48 | -118.57% | 7.26% | -21.31% | -2884.91% | |
45 Neutral | $12.05M | -1.07 | 79.78% | ― | -25.50% | -905.27% | |
43 Neutral | $1.24M | -0.06 | -219.35% | ― | -12.24% | 17.56% | |
42 Neutral | $45.34M | -3.43 | -58.30% | ― | 17.50% | 24.63% | |
34 Underperform | $26.33M | -0.10 | -151.30% | ― | -31.20% | -796.06% |
* Consumer Defensive Sector Average
BHST
BioHarvest Sciences
1.85
-6.11
-76.76%
FMC
FMC
10.66
-27.30
-71.92%
SEED
Origin Agritech
0.99
-0.18
-15.64%
RKDA
Arcadia Biosciences
0.51
-3.34
-86.70%
BIOX
Bioceres Crop Solutions
0.40
-2.47
-85.92%
CTVA
Corteva
82.40
8.79
11.95%
BioHarvest Sciences Corporate Events
BioHarvest Secures First CDMO Manufacturing Deal and Posts Modest Q2 Revenue Growth
Aug 12, 2026
On August 11, 2026, BioHarvest Sciences reported second-quarter 2026 revenue of $8.8 million, up 3.8% year-on-year, with gross margins of 58% and a net loss narrowed to $3.7 million, while operating losses and adjusted EBITDA loss increased as the...
BioHarvest Sciences Files Q2 2026 Interim Financials and MD&A
Aug 11, 2026
BioHarvest Sciences Inc. filed a Form 6-K for August 2026, providing investors with unaudited interim condensed consolidated financial statements and related disclosures for the three and six months ended June 30, 2026. The filing underscores the ...
BioHarvest Sciences to Spotlight Botanical Synthesis Platform at Canaccord Genuity Growth Conference
Jul 29, 2026
BioHarvest Sciences announced on July 29, 2026, that CEO Zaki Rakib will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, a key forum for global institutional investors focused on growth companies in technology, healthcare...
BioHarvest Sciences Sets August 11 Date for Q2 2026 Results and Investor Call
Jul 28, 2026
BioHarvest Sciences announced on July 28, 2026, that it will release its second quarter 2026 financial results before market open on Tuesday, August 11, 2026. The company will hold a conference call and webcast at 8:00 a.m. Eastern Time the same d...
BioHarvest Sciences to Showcase Botanical Synthesis at 2026 BIO International Convention
Jun 18, 2026
BioHarvest Sciences Inc., listed on NASDAQ and FSE, develops sustainable plant-derived compounds using its proprietary Botanical Synthesis platform. The company positions itself at the intersection of pharmaceutical innovation and nutraceutical we...
BioHarvest Sciences Files Form 6-K With Meeting Materials for Upcoming Shareholder Vote
May 28, 2026
BioHarvest Sciences Inc., a foreign private issuer based in Vancouver, British Columbia, operates under the Canadian regulatory framework while maintaining a U.S. listing that requires it to file continuous disclosure documents with the SEC. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.